{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:48Z","timestamp":1791906468929,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101136703"],"award-info":[{"award-number":["101136703"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trecan.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:29:52Z","timestamp":1787948992000},"page":"898-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Accelerating rare cancer research: a Zebrafish-First Triage Strategy"],"prefix":"10.1016","volume":"12","author":[{"given":"Bruno","family":"Lopes-Bastos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-047X","authenticated-orcid":false,"given":"Ewa","family":"Snaar-Jagalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.08.001_bb0005","article-title":"Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN","volume":"39","author":"Blay","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.trecan.2026.08.001_bb0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41573-021-00210-8","article-title":"Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials","volume":"20","author":"Patton","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.08.001_bb0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.trecan.2020.02.006","article-title":"Pediatric cancer models in zebrafish","volume":"6","author":"Casey","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.08.001_bb0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature09806","article-title":"The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset","volume":"471","author":"Ceol","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.001_bb0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-022-04584-6","article-title":"Anatomic position determines oncogenic specificity in melanoma","volume":"604","author":"Weiss","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.001_bb0030","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1038\/s41467-025-61937-1","article-title":"Specific oncogene activation of the cell of origin in mucosal melanoma","volume":"16","author":"Babu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.001_bb0035","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1158\/0008-5472.CAN-25-5299","article-title":"GNAQ induces melanomagenesis in Mitfa-independent melanocyte progenitors in a zebrafish model of uveal melanoma","volume":"86","author":"Yevdash","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.001_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.69703","article-title":"Shifting the focus of zebrafish toward a model of the tumor microenvironment","volume":"11","author":"Weiss","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.trecan.2026.08.001_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.5094","article-title":"Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target","volume":"245","author":"Cao","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2026.08.001_bb0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10456-024-09930-y","article-title":"Lactate secreted by glycolytic conjunctival melanoma cells attracts and polarizes macrophages to drive angiogenesis in zebrafish xenografts","volume":"27","author":"Yin","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.trecan.2026.08.001_bb0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41420-023-01446-6","article-title":"Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target","volume":"9","author":"Groenewoud","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.trecan.2026.08.001_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/jpet.119.260299","article-title":"Mechanistic and quantitative understanding of pharmacokinetics in zebrafish larvae through nanoscale blood sampling and metabolite modeling of paracetamol","volume":"371","author":"Van Wijk","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.trecan.2026.08.001_bb0065","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1038\/s41467-024-49051-0","article-title":"Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer","volume":"15","author":"Costa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.001_bb0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-025-00882-0","article-title":"Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancer","volume":"9","author":"Mendes","year":"2025","journal-title":"npj Precis. Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:13:09Z","timestamp":1791904389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326001871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405803326001871"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.001","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating rare cancer research: a Zebrafish-First Triage Strategy","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}